{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:42Z","timestamp":1777385502147,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/tpj.2017.32","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T10:01:25Z","timestamp":1499767285000},"page":"431-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus"],"prefix":"10.1038","volume":"18","author":[{"given":"S","family":"Prudente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5837-9111","authenticated-orcid":false,"given":"R","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Pezzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Garofolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Lamacchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Filardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G C","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Alberico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G","family":"Scarale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Penno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cignarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Copetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Trischitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"BFtpj201732_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197\u20132223.","journal-title":"Lancet"},{"key":"BFtpj201732_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"DR Whiting","year":"2011","unstructured":"Whiting DR, Guariguata L, Weil C, Shaw J . IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311\u2013321.","journal-title":"Diabetes Res Clin Pract"},{"key":"BFtpj201732_CR3","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1210\/jc.2009-1966","volume":"95","author":"RJ Smith","year":"2010","unstructured":"Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI . Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95: 1566\u20131574.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201732_CR4","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.2337\/dc15-2829","volume":"39","author":"D Giugliano","year":"2016","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Esposito K . Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59. Diabetes Care 2016; 39: S86\u2013S87.","journal-title":"Diabetes Care"},{"key":"BFtpj201732_CR5","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.2337\/dci16-0003","volume":"39","author":"WH Herman","year":"2016","unstructured":"Herman WH, Kalyani RR, Wexler DJ, Matthews DR, Inzucchi SE . Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59. Diabetes Care 2016; 39: S88\u2013S89.","journal-title":"Diabetes Care"},{"key":"BFtpj201732_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2337\/dc13-0512","volume":"36","author":"I Raz","year":"2013","unstructured":"Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013; 36: 1779\u20131788.","journal-title":"Diabetes Care"},{"key":"BFtpj201732_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40291-012-0002-7","volume":"16","author":"GC Mannino","year":"2012","unstructured":"Mannino GC, Sesti G . Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 2012; 16: 285\u2013302.","journal-title":"Mol Diagn Ther"},{"key":"BFtpj201732_CR8","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.2337\/db13-1966","volume":"63","author":"S Prudente","year":"2014","unstructured":"Prudente S, Morini E, Lucchesi D, Lamacchia O, Bailetti D, Mercuri L et al. IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy. Diabetes 2014; 63: 3135\u20133140.","journal-title":"Diabetes"},{"key":"BFtpj201732_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1172\/JCI118705","volume":"97","author":"K Almind","year":"1996","unstructured":"Almind K, Inoue G, Pedersen O, Kahn CR . A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996; 97: 2569\u20132575.","journal-title":"J Clin Invest"},{"key":"BFtpj201732_CR10","first-page":"2004","volume":"85","author":"ML Hribal","year":"2000","unstructured":"Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D et al. The Gly\u2014>Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000; 85: 2004\u20132013.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201732_CR11","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/j.1582-4934.2008.00246.x","volume":"12","author":"ML Hribal","year":"2008","unstructured":"Hribal ML, Tornei F, Pujol A, Menghini R, Barcaroli D, Lauro D et al. Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion. J Cell Mol Med 2008; 12: 2096\u20132106.","journal-title":"J Cell Mol Med"},{"key":"BFtpj201732_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(95)92779-4","volume":"346","author":"JO Clausen","year":"1995","unstructured":"Clausen JO, Hansen T, Bj\u00f8rbaek C, Echwald SM, Urhammer SA, Rasmussen S et al. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 1995; 346: 397\u2013402.","journal-title":"Lancet"},{"key":"BFtpj201732_CR13","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jc.2002-021716","volume":"88","author":"MA Marini","year":"2003","unstructured":"Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 3368\u20133371.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtpj201732_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ng.866","volume":"43","author":"TO Kilpel\u00e4inen","year":"2011","unstructured":"Kilpel\u00e4inen TO, Zillikens MC, Stan\u010d\u00e1kova A, Finucane FM, Ried JS, Langenberg C et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 2011; 43: 753\u2013760.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ng.2274","volume":"44","author":"AK Manning","year":"2012","unstructured":"Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012; 44: 659\u2013669.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR16","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/ng.443","volume":"41","author":"J Rung","year":"2009","unstructured":"Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proen\u00e7a C et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009; 41: 1110\u20131115.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa072366","volume":"357","author":"NJ Samani","year":"2007","unstructured":"Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443\u2013453.","journal-title":"N Engl J Med"},{"key":"BFtpj201732_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature09270","volume":"466","author":"TM Teslovich","year":"2010","unstructured":"Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707\u2013713.","journal-title":"Nature"},{"key":"BFtpj201732_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng.609","volume":"42","author":"BF Voight","year":"2010","unstructured":"Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579\u2013589.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR20","doi-asserted-by":"publisher","first-page":"e1002695","DOI":"10.1371\/journal.pgen.1002695","volume":"8","author":"CS Fox","year":"2012","unstructured":"Fox CS, Liu Y, White CC, Feitosa M, Smith AV, Heard-Costa N et al. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. PLoS Genet 2012; 8: e1002695.","journal-title":"PLoS Genet"},{"key":"BFtpj201732_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ng.2897","volume":"46","author":"A Mahajan","year":"2014","unstructured":"Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014; 46: 234\u2013244.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR22","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45: 1274\u20131283.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR23","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1093\/ndt\/gfs148","volume":"27","author":"S De Cosmo","year":"2012","unstructured":"De Cosmo S, Prudente S, Lamacchia O, Lucchesi D, Shah H, Mendonca C et al. The 9p21 coronary artery disease locus and kidney dysfunction in patients with Type 2 diabetes mellitus. Nephrol Dial Transplant 2012; 27: 4411\u20134413.","journal-title":"Nephrol Dial Transplant"},{"key":"BFtpj201732_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.gene.2011.11.055","volume":"493","author":"F Paladini","year":"2012","unstructured":"Paladini F, Adinolfi V, Cocco E, Ciociola E, Tamburrano G, Cascino I et al. Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1. Gene 2012; 493: 278\u2013281.","journal-title":"Gene"},{"key":"BFtpj201732_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263\u2013265.","journal-title":"Bioinformatics"},{"key":"BFtpj201732_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/ng1669","volume":"37","author":"PI de Bakker","year":"2005","unstructured":"de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D . Efficiency and power in genetic association studies. Nat Genet 2005; 37: 1217\u20131223.","journal-title":"Nat Genet"},{"key":"BFtpj201732_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2307\/2534018","volume":"54","author":"I Olkin","year":"1998","unstructured":"Olkin I, Sampson A . Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics 1998; 54: 317\u2013322.","journal-title":"Biometrics"},{"key":"BFtpj201732_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2337\/diacare.27.6.1394","volume":"27","author":"G Sesti","year":"2004","unstructured":"Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004; 27: 1394\u20131398.","journal-title":"Diabetes Care"},{"key":"BFtpj201732_CR29","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1007\/s00125-009-1426-4","volume":"52","author":"E Morini","year":"2009","unstructured":"Morini E, Prudente S, Succurro E, Chandalia M, Zhang YY, Mammarella S et al. IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants. Diabetologia 2009; 52: 1852\u20131857.","journal-title":"Diabetologia"},{"key":"BFtpj201732_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.2337\/diabetes.50.4.882","volume":"50","author":"M Stumvoll","year":"2001","unstructured":"Stumvoll M, Fritsche A, Volk A, Stefan N, Madaus A, Maerker E et al. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans. Diabetes 2001; 50: 882\u2013885.","journal-title":"Diabetes"},{"key":"BFtpj201732_CR31","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1096\/fj.01-0009rev","volume":"15","author":"G Sesti","year":"2001","unstructured":"Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R . Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15: 2099\u20132111.","journal-title":"FASEB J"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201732","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2017.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:47:59Z","timestamp":1684622879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFtpj201732"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2017.32","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]},"assertion":[{"value":"27 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}